


Aberrant methylation of *MUC1* and *MUC4* promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas

SUPPLEMENTARY FIGURE AND TABLES



Supplementary Figure S1: Effect of hypoxia treatment for expression level of *MUC1* and *MUC4* mRNA. Expression of *CAIX*, *MUC1* and *MUC4* mRNA examined by quantitative real time RT-PCR. The bar graphs show gene expression levels relative to those in non-treatment of hypoxia.

Supplementary Table S1: Comparison between neoplastic and non-neoplastic regions

	Neoplastic region		Non-neoplastic region		<i>p</i> value
	n	mean ± sd	n	mean ± sd	
Methylation status of					
<i>MUC1</i>	103	51.3 ± 17.1	164	58.0 ± 17.6	<0.001**
<i>MUC4</i>	103	71.7 ± 18.1	164	68.6 ± 13.7	0.145*
mRNA expression level of					
<i>MUC1</i>	103	1.2 ± 0.7	163	1.1 ± 0.7	0.443**
<i>MUC4</i>	103	-0.4 ± 1.2	162	-1.2 ± 0.8	<0.001*
<i>TET1</i>	101	0.0 ± 0.5	161	0.2 ± 0.6	<0.001**
<i>TET2</i>	103	0.6 ± 0.5	163	0.8 ± 0.3	<0.001**
<i>TET3</i>	103	0.0 ± 0.4	163	0.0 ± 0.4	0.343**
<i>AID</i>	103	2.0 ± 0.7	163	1.9 ± 0.8	0.294
<i>DNMT1</i>	103	-0.1 ± 0.5	164	0.1 ± 0.4	<0.001
<i>DNMT3a</i>	103	0.6 ± 0.3	163	0.7 ± 0.3	0.059
<i>CAIX</i>	103	-0.1 ± 1.3	162	-0.9 ± 1.1	<0.001*

p value is calculated by equal variant t.test, Unequal variant t.test (*) or Mann-Whitney U test (**).

Supplementary Table S2: Summarized correlation coefficient (R)

Supplementary Table S3: Synthetic oligonucleotides used in the study**RT-PCR**

MUC1			Forward: 5'-CCAGCACCGACTACTACCAAGAG-3' Reverse: 5'-CGTCGTGGACATTGATGGT-3'
MUC4			Forward: 5'-TGGGACGATGCTGACTTCTC-3' Reverse: 5'-CCCCGTTGTTGTCATCTTC-3'
TET1			Forward: 5'-CCCGAATCAAGCGGAAGAATA-3' Reverse: 5'-TACTTCAGGTTGCACGGT-3'
TET2			Forward: 5'-AAGGCTGAGGGACGAGAACGA-3' Reverse: 5'-TGAGCCCATCTCCTGCTTCCA-3'
TET3			Forward: 5'-CCTGCCGATGACAAGCTGGA-3' Reverse: 5'-GAGTTCCCGGATAGAGGCGA-3'
AID			Forward: 5'-AAAATGTCCGCTGGGCTAAG-3' Reverse: 5'-AGGTCCCAGTCCGAGATGTAG-3'
DNMT1			Forward: 5'-GAGGAAGCTGCTAAGGACTAGTTC-3' Reverse: 5'-ACTCCACAATTGATCACTAAATC-3'
DNMT3a			Forward: 5'-ACAAGAATGCCACCAAAGCAG-3' Reverse: 5'-TCATCCACCAAGACACAATGC-3'
CAIX			Forward: 5'-CGGAAGAAAACAGTGCCTATGAG-3' Reverse: 5'-CAGGGCGGTGTAGTCAGAGA-3'
β-actin			Forward: 5'-CTCTCCAGCCTCCTCCTG-3' Reverse: 5'-GAAGCATTGCGGTGGACGAT-3'
MSE			
MUC1	1st		Forward: 5'-AAAGGGGGAGGTTAGTTGGA-3' Reverse: 5'-TACCCCTCACCTATAAACAC-3'
	2nd		Forward: 5'-[GC clamp*] AAGAGGTAGGAGGTAGGGGA-3' Reverse: 5'-AAAACAAAACAAATTCAAAC-3'
MUC4	1st		Forward: 5'-AGAGTAAGGGGTGTATGGGTG-3' Reverse: 5'-AACCTACCCCTTCATAAC-3'
	2nd		Forward: 5'-[GC clamp*] AGGAGAGAAAAGGGTGATTAG-3' Reverse: 5'-ACTCCACTACCCAACAAC-TAC-3'

*GC clamp: 5'-CGCCCGCCCGCGCGCGGGCGGGCGGGGCACGGGGG-3'.